EP
KRRO icon

Eversept Partners’s Korro Bio KRRO Stock Holding History

Eversept Partners’s Portfolio KRRO Stock Details KRRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-1,358
Closed -$479K – 121
2021
Q3 		$479K Sell
1,358
-492
-27% -$194K 0.03% 100
2021
Q2 		$921K Sell
1,850
-2,022
-52% -$987K 0.06% 79
2021
Q1 		$1.84M Buy
+3,872
New +$7.52M 0.14% 63

Other funds holding KRRO

AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
7IH
72 Investment Holdings Stamford, Connecticut $49.6M AUM 684.72% 1-Year Est. Return

Eversept Partners's KRRO Position: Q4 2025 in Review

Eversept Partners sold out of Korro Bio (KRRO) in Q4 2025, closing a stake of 20,856 shares — an estimated $999K sold.

Eversept Partners first reported a position in KRRO in Q3 2021 and held it in 2 quarters. The position peaked at $999K in Q3 2025. 83 funds tracked by Wall St. Rank hold KRRO as of Q4 2025.

  • Eversept Partners reported no remaining Korro Bio position as of Q4 2025 after selling out during the quarter.
  • Eversept Partners sold 20,856 Korro Bio shares in Q4 2025, an estimated $999K.
  • Eversept Partners first reported a position in Korro Bio in Q3 2021 and held it in 2 quarters.
  • Eversept Partners's Korro Bio position peaked at $999K in Q3 2025.
  • 83 funds tracked by Wall St. Rank held Korro Bio as of Q4 2025.

Based on Eversept Partners's 13F filing for Q4 2025, filed 17 Feb 2026.